Zenas Biopharma Inc (ZBIO)

NASD · Healthcare · Biotechnology · USA

Zenas Biopharma Inc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.

Zenas Biopharma is a clinical stage biopharmaceutical company developing immunology-based therapies for autoimmune diseases. Its lead candidate, obexelimab, is a bifunctional monoclonal antibody targeting B cells through CD19 and FcγRIIb binding. The company also develops orelabrutinib, a BTK inhibitor for progressive multiple sclerosis, alongside early-stage candidates for various immunology indications.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Zenas Biopharma Inc stock.

Our verdict on ZBIO

Not valued: We cannot value this company yet.

We do not publish a value for this company: its filings cover three fiscal years and projecting growth needs four in a row.

ETFs with the most weight in ZBIO

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than ZBIO in Biotechnology

129 more in this industry show a wider margin of safety.

Is ZBIO undervalued or overvalued?

We do not publish a verdict on ZBIO yet. A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover three fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.

What is the intrinsic value of ZBIO?

We do not publish one (as of the 2026-11-17 close). A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover three fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.